Product Information
CARBAMAZEPINE ER 400 MG TABLET is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $0.6528 per EA under NDC 00832602411. Its NADAC has been published 240 times since Mar 2, 2022.
FDA first approved this application on Apr 13, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
00832602411
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA213311FDA Approved
4/13/2021
TE Code
AB
On Market Since
4/13/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBAMAZEPINE ER 400 MG TABLET has been published 240 times since Mar 2, 2022, and over the history we have for it it has declined 58.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6528 per EA |
|---|---|
| All-time high | $1.8329 (Jun 15, 2022) |
| All-time low | $0.5156 (Nov 20, 2024) |
| 52-week high | $0.7270 |
| 52-week low | $0.5655 |
| Median price | $0.7668 |
| Average price | $0.9592 |
| Largest weekly change | +78.1% (May 17, 2023) |
| Weeks tracked | 240 |
| Tracking since | Mar 2, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBAMAZEPINE ER 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CARBAMAZEPINE ER 400 MG TABLET, manufactured by Upsher-Smith Laboratories LLC, is $0.6528 per EA (NDC 00832602411), effective Sep 30, 2026.
How has the price of CARBAMAZEPINE ER 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for CARBAMAZEPINE ER 400 MG TABLET has declined 58.0%. It has been tracked across 240 weekly CMS publications since Mar 2, 2022.
What are the highest and lowest recorded NADAC prices for CARBAMAZEPINE ER 400 MG TABLET?
Since Mar 2, 2022, the NADAC for CARBAMAZEPINE ER 400 MG TABLET has ranged from a low of $0.5156 (Nov 20, 2024) to a high of $1.8329 (Jun 15, 2022), with a median of $0.7668 per EA.
Are there cheaper alternatives to CARBAMAZEPINE ER 400 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBAMAZEPINE ER 400 MG TABLET, is $0.6009 per EA — about 8% below CARBAMAZEPINE ER 400 MG TABLET.
Who manufactures CARBAMAZEPINE ER 400 MG TABLET?
CARBAMAZEPINE ER 400 MG TABLET (NDC 00832602411) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.